Prior art that covers safety profiles, dosing, pharmacokinetics, pharmacodynamics could help the repurposing of drug-leads and speed up the drug development process of TLR9 targeting drug candidates for COVID-19. The gene discussed is TLR9; the disease is COVID-19.